Ask your body for more of its own growth hormone.
A physician-prescribed blend of two peptides that signal the pituitary gland to release growth hormone. Evaluated by a licensed Apex MD provider and filled by a licensed U.S. pharmacy.
SPENGA members: $50 off with code SPENGA50
CJC-1295 is a modified copy of the first 29 amino acids of growth-hormone-releasing hormone (GHRH), the signal your brain already uses to call for growth hormone. Ipamorelin is a five-amino-acid peptide that mimics ghrelin at a second, separate receptor.
Neither one is growth hormone. Both ask your pituitary gland to release its own, which keeps your body's feedback loops in the picture.
CJC-1295 binds the GHRH receptor on the pituitary cells that make growth hormone. Ipamorelin binds the growth hormone secretagogue receptor. Because they work through different doors, the two are paired on the reasoning that the combined signal is stronger than either alone.
Released growth hormone then prompts the liver to make IGF-1, which carries out much of growth hormone's downstream work. Your provider tracks IGF-1 to see how you are responding.
Every finding is labelled by the kind of study it came from, with the source linked.
In two placebo-controlled trials in healthy adults, a single dose of long-acting CJC-1295 raised average growth hormone two to ten times for six days or more, and IGF-1 one and a half to three times for nine to eleven days.
Teichman et al., J Clin Endocrinol Metab, 2006In healthy men, CJC-1295 raised baseline growth hormone while the body's natural pulsing pattern of release was preserved.
Ionescu & Frohman, J Clin Endocrinol Metab, 2006In 40 healthy men given ipamorelin by infusion, growth hormone peaked in under an hour and returned to baseline within about six hours.
Gobburu et al., Pharmaceutical Research, 1999Ipamorelin released growth hormone without a meaningful rise in cortisol or ACTH in animal work, which is why it is described as a selective secretagogue.
Raun et al., Eur J Endocrinol, 1998No human trial has tested this combination, and the CJC-1295 studies used its long-acting form. Human studies measured hormone levels, not muscle, fat loss, sleep or recovery. Reports of those benefits come from patient experience.
Sigalos & Pastuszak, Sexual Medicine Reviews, 2018Published research describes what was observed in a study. It is not a promise of what any product will do for you. Your provider will talk through what is realistic.
A small injection just under the skin, usually in the evening on an empty stomach. Your provider sets the dose and the weekly schedule and teaches you the technique. It arrives already reconstituted by the pharmacy, so there is no powder to mix and nothing to measure out.
Patients most often describe changes in sleep and recovery first, with body-composition changes later. These are patient reports, not trial outcomes, and results vary.
Growth hormone signalling can raise blood sugar, so your provider checks IGF-1 and glucose markers at baseline and again during treatment.
Your provider reviews your full history. Tell them about every medication and condition, including any history of cancer.
CJC-1295 and ipamorelin are both named on the World Anti-Doping Agency Prohibited List and are banned at all times, in and out of competition.
No. These peptides signal your pituitary gland to release your own growth hormone rather than supplying it. Human studies confirm they raise growth hormone and IGF-1, which is different from proving a specific clinical benefit.
No. Neither peptide is approved by the FDA for any condition. When prescribed it is a compounded medication, which has not been reviewed by the FDA for safety, effectiveness or quality.
That has not been demonstrated in human clinical trials of these peptides. Studies in people measured hormone levels. Your provider will talk through what is realistic for you.
As a small subcutaneous injection, usually in the evening. Your provider sets the dose and schedule and monitors your labs.
The most commonly reported are injection-site irritation, flushing, headache, water retention and increased appetite. Blood sugar can rise, which is why labs are monitored. Long-term safety has not been studied.
No. Both peptides are on the WADA Prohibited List and are banned at all times. Military members should also check their service's prohibited list.
BPC-157 and TB-500 together: the two most talked-about recovery peptides, prescribed as one protocol and overseen by a physician.
The Wolverine pairing with GHK-Cu added: a copper-carrying peptide your body makes naturally and that has been studied for skin.
A 15-amino-acid peptide modelled on a protective protein from the stomach, studied in animal models for tendon, muscle and ligament repair.
Answer a few questions. A licensed Apex MD provider decides whether it is right for you.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Prescription products require an online evaluation with a licensed medical professional, who will determine whether a prescription is appropriate. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness or quality. Research cited on this site describes published studies and is not a claim about what any product will do for you. Individual results vary.
